Acquisition - Alcon will acquire STAAR Surgical for \$28 per share in cash, representing a ~59% premium to STAAR's 90-day volume-weighted average price[15] - The acquisition represents a total equity value of approximately \$1.5 billion and is expected to be funded through short- and long-term credit facilities[15] - The acquisition is expected to be accretive to core diluted EPS in year two[15] Financial Highlights (Q2 2025) - Net sales reached \$2.6 billion, a 4% increase year-over-year on a reported basis and a 3% increase in constant currency[21] - Core operating margin was 19.1%, a decrease of 70 basis points[21] - Core diluted EPS was \$0.76, compared to \$0.74 in Q2 2024[20] Financial Highlights (1H 2025) - Net sales reached \$5.0 billion[26] - Free cash flow was \$681 million[20] Product Mix (1H 2025 Sales) - Vision Care accounted for 45% (\$2.2 billion) of sales, while Surgical accounted for 55% (\$2.8 billion)[27] - Within Vision Care, contact lenses represented 62% of sales[27] - Within Surgical, consumables represented 53% of sales[27] FY 2025 Outlook (Updated) - Net sales are projected to be between \$10.3 to \$10.4 billion[64] - Core operating margin is expected to be between 19.5% to 20.5%[64] - Core diluted EPS is maintained at \$3.05 to \$3.15[64]

June 2025 We are the Optejet® Company An FDA-registered Class I Medical Device Forward-looking Statements Except for historical information, all the statements, expectations, and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other statements relating to our future activities or other future events or conditions, including esti ...